<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359008</url>
  </required_header>
  <id_info>
    <org_study_id>PHP V3</org_study_id>
    <nct_id>NCT00359008</nct_id>
  </id_info>
  <brief_title>PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)</brief_title>
  <official_title>PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Notal Vision Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Notal Vision Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the ability of the PHP &amp; HPHP to detect
      newly diagnosed non treated Chorodial neovascularization (CNV) lesion associate with advanced
      age related Macular Degeneration (AMD) and differentiate them from Early/intermediate/GA AMD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the study is prospective, multi-center, comparative

      The PHP is a class I FDA approved Device ( K050350 )
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">336</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Intermediate AMD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>New untreated CNV subject</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        At least 200 subjects with intermediate AMD in at least one (1) eye based on medical record
        review and/or clinical diagnosis and at least 200 subjects with neovascular AMD in at least
        one (1) eye in all sites.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AMD related lesions:

        Newly diagnosed (up to 6 months) non-treated CNV patients secondary to AMD in the study
        eye, or GA patients or Early and Intermediate AMD patients.

          -  Age Â³ 50 for AMD patients

          -  VA with habitual correction in study eye 6/60 or better

          -  Mental and physical ability to perform a PHP/HPHP test

          -  Subject able and willing to sign consent form and participate in study

          -  Subject is not participating in another study when conducting the test

        Exclusion Criteria:

          -  Evidence of macular disease other than AMD or Glaucoma in the study eye.

               -  Presence of any significant media opacity that precludes a clear view of the
                  macular area as identified by biomicroscopy, fundus photography, or fluorescein
                  angiography in the study eye

               -  Any non-macular related ocular surgery performed within 3 months prior to the
                  study in the study eye

               -  CNV patient inability to tolerate intravenous fluorescein angiography
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofer Sharon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Notal Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ha'emek Hospital</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.notalvision.com</url>
    <description>Company Site</description>
  </link>
  <reference>
    <citation>Alster Y, Bressler NM, Bressler SB, Brimacombe JA, Crompton RM, Duh YJ, Gabel VP, Heier JS, Ip MS, Loewenstein A, Packo KH, Stur M, Toaff T; Preferential Hyperacuity Perimetry Research Group. Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology. 2005 Oct;112(10):1758-65.</citation>
    <PMID>16154198</PMID>
  </reference>
  <reference>
    <citation>Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H, Springer A, Schachat AP, Bressler NM, Bressler SB, Cooney MJ, Alster Y, Rafaeli O, Malach R; Preferential Hyperacuity Perimeter Research Group. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina. 2005 Apr-May;25(3):296-303.</citation>
    <PMID>15805906</PMID>
  </reference>
  <reference>
    <citation>Bressler NM. Age-related macular degeneration is the leading cause of blindness... JAMA. 2004 Apr 21;291(15):1900-1.</citation>
    <PMID>15108691</PMID>
  </reference>
  <reference>
    <citation>Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract. 2002 Mar-Apr;15(2):142-52. Review.</citation>
    <PMID>12002198</PMID>
  </reference>
  <reference>
    <citation>Enoch JM, Williams RA, Essock EA, Barricks M. Hyperacuity perimetry. Assessment of macular function through ocular opacities. Arch Ophthalmol. 1984 Aug;102(8):1164-8.</citation>
    <PMID>6466179</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2006</study_first_submitted>
  <study_first_submitted_qc>July 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2006</study_first_posted>
  <last_update_submitted>January 10, 2008</last_update_submitted>
  <last_update_submitted_qc>January 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Osnat Ehrman</name_title>
    <organization>NotalVision</organization>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>CNV</keyword>
  <keyword>PHP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

